BAXTER INTL DL 1 chart

Last update: 2022-08-12
Key statistics and financials
Revenue per share 29.36
Dividend & YieldN/A€ (N/A)
Beta 0.59
Market capitalization 29.61B
Operating cash flow 1.46B
ESG Scores 23.7

Company description

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Sector: Healthcare - Industry: Medical Instruments & Supplies

Financial Ratios
Quick Ratio1.52
Working Capital0.28
Return On Equity0.14
Debt To Equity1.88
Fixed Asset Ratio0.27
Fixed Interest Cover10.15

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 60M -23M 57M 104M
Total Cashflows From Investing Activities -916M -1.1B -1.18B -11.2B
Net Borrowings 1.88B 1.88B 478M 9.33B
Total Cash From Financing Activities -2.6B 498M -345M 8.24B
Change To Operating Activities -99M -354M -48M -58M
Issuance Of Stock 258M 356M 202M 187M
Net Income 1.55B 1B 1.1B 1.28B
Change In Cash -1.56B 1.5B 401M -780M
Effect Of Exchange Rate -63M -5M 57M -47M
Total Cash From Operating Activities 2.02B 2.1B 1.87B 2.22B
Depreciation 762M 784M 823M 890M
Change To Account Receivables -12M -52M -119M -170M
Other Cashflows From Financing Activities -33M -48M -52M -138M
Change To Netincome -43M 744M 215M 209M
Capital Expenditures -659M -696M -709M -743M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 618M 561M 495M 529M
Income Before Tax 1.62B 970M 1.29B 1.48B
Net Income 1.55B 1B 1.1B 1.28B
Selling General Administrative 2.4B 2.44B 2.36B 2.63B
Gross Profit 4.81B 4.82B 4.73B 5.25B
Ebit 1.8B 1.82B 1.88B 2.09B
Operating Income 1.8B 1.82B 1.88B 2.09B
Interest Expense -93M -111M -153M -206M
Income Tax Expense 65M -41M 182M 182M
Total Revenue 11.1B 11.36B 11.67B 12.78B
Cost Of Revenue 6.29B 6.54B 6.94B 7.53B
Total Other Income ExpenseNet -184M -852M -586M -614M
Net Income From Continuing Ops 1.55B 1.01B 1.11B 1.29B
Net Income Applicable To Common Shares 1.55B 1B 1.1B 1.28B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 7.85B 10.28B 11.29B 24.4B
Total Stockholder Equity 7.84B 7.88B 8.69B 9.08B
Other Current Liabilities 1B 874M 923M 1.21B
Total Assets 15.72B 18.19B 20.02B 33.52B
Common Stock 683M 683M 683M 683M
Other Current Assets 614M 619M 688M 755M
Retained Earnings 15.07B 15.72B 16.33B 17.07B
Treasury Stock -13.81B -14.47B -14.37B -14.87B
Cash 1.84B 3.33B 3.73B 2.95B
Total Current Liabilities 2.81B 3.23B 3.33B 4.24B
Other Stockholder Equity -3.82B -3.71B -3.31B -3.38B
Property, Plant, and Equipment 4.53B 5.12B 5.33B 5.81B
Total Current Assets 5.96B 7.5B 8.41B 8.87B
Net Tangible Assets 3.43B 3.38B 3.8B -8.55B
Net Receivables 1.84B 1.9B 2.08B 2.71B
Accounts Payable 998M 892M 1.04B 1.25B


Insider Transactions

Here are the insider transactions of stock shares related to BAXTER INTL DL 1:

Filer Name Transaction Text Ownership Date Filer Relation Shares
ROSENBLOOM DAVID SStock Award(Grant) at price 0.00 per share.D2022-06-01General Counsel41.58k
WILVER PETER MStock Award(Grant) at price 0.00 per share.D2022-05-10Director2.48k
SHAFER DAVID BRENTStock Award(Grant) at price 0.00 per share.D2022-05-10Director2.48k
HELLMAN PETER SStock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
STROUCKEN ALBERT P LStock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
OESTERLE STEPHEN NStock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
MORRISON PATRICIA BStock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
SMITH CATHERINE RStock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
CHEN THOMAS FANG TYANStock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
SCHLICHTING NANCY MStock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
WENDELL AMY MCBRIDEStock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
MAHONEY MICHAEL FStock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
WILKES DAVID S. M.D.Stock Award(Grant) at price 0.00 per share.D2022-05-03Director2.71k
HELLMAN PETER SSale at price 75.76 - 76.63 per share.D2022-04-05Director4.02k
HELLMAN PETER SConversion of Exercise of derivative security at price 29.52 per share.D2022-04-05Director4.02k
STROUCKEN ALBERT P LSale at price 75.76 - 76.63 per share.D2022-04-05Director4.02k
STROUCKEN ALBERT P LConversion of Exercise of derivative security at price 29.52 per share.D2022-04-05Director4.02k
FORSYTH JOHN DSale at price 77.68 per share.D2022-04-01Director1k
FORSYTH JOHN DConversion of Exercise of derivative security at price 29.52 per share.D2022-04-01Director1k
ALMEIDA JOSE E.Stock Award(Grant) at price 0.00 per share.D2022-03-02Chief Executive Officer32.7k
MASON JEANNE KStock Award(Grant) at price 0.00 per share.D2022-03-02Officer5.05k
BORZI JAMES WStock Award(Grant) at price 0.00 per share.D2022-03-02Officer4.16k
MARTIN SEAN B WStock Award(Grant) at price 0.00 per share.D2022-03-02General Counsel6.69k
STEVENS BRIANStock Award(Grant) at price 0.00 per share.D2022-03-02Officer12.48k
SACCARO JAMESStock Award(Grant) at price 0.00 per share.D2022-03-02Chief Financial Officer10.7k
ACCOGLI GIUSEPPEStock Award(Grant) at price 0.00 per share.D2022-03-02Chief Operating Officer11.89k
FRYE ANDREW RICHARDStock Award(Grant) at price 0.00 per share.D2022-03-02Officer7.43k
FRANZI CRISTIANOStock Award(Grant) at price 0.00 per share.D2022-03-02Officer8.18k
KUNZLER JACQUELINEStock Award(Grant) at price 0.00 per share.D2022-03-02Officer2.97k
FORSYTH JOHN DSale at price 84.82 per share.D2022-03-01Director1k
FORSYTH JOHN DConversion of Exercise of derivative security at price 29.52 per share.D2022-03-01Director1k
STEVENS BRIANSale at price 85.46 - 86.07 per share.D2022-02-28Officer2.5k
MASON JEANNE KSale at price 84.75 - 85.54 per share.D2022-02-14Officer54.14k
MASON JEANNE KConversion of Exercise of derivative security at price 30.95 per share.D2022-02-14Officer54.14k
ALMEIDA JOSE E.Stock Award(Grant) at price 0.00 per share.D2022-02-10Chief Executive Officer39.01k
MASON JEANNE KStock Award(Grant) at price 0.00 per share.D2022-02-10Officer5.19k
MARTIN SEAN B WStock Award(Grant) at price 0.00 per share.D2022-02-10General Counsel6.24k
STEVENS BRIANStock Award(Grant) at price 0.00 per share.D2022-02-10Officer973
SACCARO JAMESStock Award(Grant) at price 0.00 per share.D2022-02-10Chief Financial Officer10.14k
ACCOGLI GIUSEPPEStock Award(Grant) at price 0.00 per share.D2022-02-10Chief Operating Officer8.58k
FRYE ANDREW RICHARDStock Award(Grant) at price 0.00 per share.D2022-02-10Officer5.46k
FRANZI CRISTIANOStock Award(Grant) at price 0.00 per share.D2022-02-10Officer6.24k
KUNZLER JACQUELINEStock Award(Grant) at price 0.00 per share.D2022-02-10Officer6.35k
CHEN THOMAS FANG TYANSale at price 84.53 per share.D2022-02-02Director1.68k
CHEN THOMAS FANG TYANConversion of Exercise of derivative security at price 35.03 per share.D2022-02-02Director1.68k
FORSYTH JOHN DSale at price 85.59 per share.D2022-02-01Director1k
FORSYTH JOHN DConversion of Exercise of derivative security at price 29.52 per share.D2022-02-01Director1k
KUNZLER JACQUELINEConversion of Exercise of derivative security at price 30.95 per share.D2022-01-07Officer2.21k
SCHLICHTING NANCY MStock Award(Grant) at price 0.00 per share.D2021-12-13Director743
MARTIN SEAN B WSale at price 79.53 - 80.03 per share.D2021-11-01General Counsel21.45k
MARTIN SEAN B WConversion of Exercise of derivative security at price 50.77 per share.D2021-11-01General Counsel21.45k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to BAXTER INTL DL 1. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on BAXTER INTL DL 1

Here is the result of two systematic investment strategies applied to BAXTER INTL DL 1. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on BAXTER INTL DL 1

The following chart shows the equity curve of the two systematic investment strategies applied to BAXTER INTL DL 1:

BAXTER INTL DL 1 automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 10.46% on the backtest period.

Performance at glance

Performance

10.46 %

Latent gain

189.96 €

Invested capital

1816.84 €

Annualized return

2.5 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on BAXTER INTL DL 1

This is the result of two momentum investment strategies applied to BAXTER INTL DL 1. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on BAXTER INTL DL 1

The following chart shows all the entries opened by the momentum investment system on BAXTER INTL DL 1:

BAXTER INTL DL 1 momentum entries
  • The first momentum investment strategy would give 7.15% of return on BAXTER INTL DL 1. That represents 221.51€ of latent gain with 3100.09€ of employed capital.
  • The second momentum investment strategy would give 4.67% of return on BAXTER INTL DL 1. That represents 157.31€ of latent gain with 3371.89€ of employed capital.
Performance at glance (1Q Momentum)

Performance

7.15 %

Latent gain

221.51 €

Invested capital

3100.09 €

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

4.67 %

Latent gain

157.31 €

Invested capital

3371.89 €

Annualized return

1.26 %

Momentum equity curve on BAXTER INTL DL 1

The following chart shows the equity curve of the two momentum strategies applied to BAXTER INTL DL 1:

BAXTER INTL DL 1 momentum equity

Note: the dividends potentially given by BAXTER INTL DL 1 are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on BAXTER INTL DL 1

The following chart shows the employed capital evolution of the two momentum strategies on BAXTER INTL DL 1 since the beginning:

BAXTER INTL DL 1

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on BAXTER INTL DL 1

Buy the dip entry openings on BAXTER INTL DL 1

BAXTER INTL DL 1

The performance achieved by the robo-advisor on BAXTER INTL DL 1 is 0%. That represents 0.0$ of latent gain with 0.0€ of employed capital. The following chart shows BAXTER INTL DL 1 stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of BAXTER INTL DL 1, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 €

Invested capital

0.0 €

Annualized return

0.0 %

Equity curve of the strategy applied to BAXTER INTL DL 1

The following chart shows the result of the investment strategy applied to BAXTER INTL DL 1:

BAXTER INTL DL 1

Note: the dividends potentially given by BAXTER INTL DL 1 are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on BAXTER INTL DL 1

The following chart shows the employed capital evolution since the beginning of the investment strategy on BAXTER INTL DL 1:

BAXTER INTL DL 1

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on BAXTER INTL DL 1

In this section, I will compare the three previous investment strategies applied to BAXTER INTL DL 1.

Equity curve comparison on BAXTER INTL DL 1

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

BAXTER INTL DL 1 investment strategy comparison

Employed capital comparison on BAXTER INTL DL 1

BAXTER INTL DL 1 investment comparison

Performance comparison on BAXTER INTL DL 1

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 10.46% 189.96€ 1816.84€ 2.5%
Momentum 1 quarter 7.15% 221.51€ 3100.09€ 1.81%
Momentum 2 quarters 4.67% 157.31€ 3371.89€ 1.26%
Non-directional 0% 0.0€ 0.0€ 0.0%
Annualized return comparison

Automatic investment

2.5 %

Momentum 1Q

1.26 %

Momentum 2Q

1.26 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with BAXTER INTL DL 1:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between BAXTER INTL DL 1 and the other stocks. There may be false positives or some missing correlated stocks. If the price of BAXTER INTL DL 1 does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name BAXTER INTL DL 1
Country United States
City Deerfield
Address One Baxter Parkway
Phone 224 948 2000
Website www.baxter.com
FullTime employees 60000
Industry Medical Instruments & Supplies
Sector Healthcare
Exchange XETRA
Ticker BTL.XETRA
Market www.xetra.com

BAXTER INTL DL 1 ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 2.8
Peer Environment Performance 2.2440350877193
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 13.6
Peer Social Performance 12.085087719298
Social Percentile unknown
Highest Controversy 3
Peer Highest Controversy Performance 1.9310344827586
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic no
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Customer Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 7.3
Peer Governance Performance 7.7398245614035
Governance Percentile unknown

ESG at glance
Total ESG Scores: 23.7
Environment Score: 2.8
Social Score: 13.6
Governance Score: 7.3

ESG Performance: AVG_PERF

Peer Group: Healthcare

Peer Esg Score Performance: 22.091551724138

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 39